



The Bridge to Good Health Care

JMS CO.,LTD.

May 9, 2025

Company name: JMS Co., Ltd.
 Name of representative: Ryuji Katsura, President and Representative Director
 (Securities code: 7702; Tokyo Stock Exchange)
 Inquiries: Yoshiki Ochiai, Head of Corporate Affairs Division
 (Telephone: +81-82-243-5844)

Notice Regarding Differences between Consolidated Financial Forecast and Actual Results for the Fiscal Year Ended March 31, 2025.

Announcement of the following discrepancy between the consolidated financial forecast for the fiscal year ended March 31, 2025 (April 1, 2024 - March 31, 2025) announced on February 7, 2025 and the actual results for the same period disclosed today.

1. Difference between consolidated financial forecast and actual results for the fiscal year ended March 31, 2025 (April 1, 2024 - March 31, 2025)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	70,000	1,000	700	250	10.21 yen
Actual results (B)	69,749	872	514	89	3.65 yen
Difference (B – A)	(250)	(127)	(185)	(160)	
Difference (%)	(0.4)	(12.7)	(26.4)	(64.2)	
<Reference> Actual results for previous fiscal year ended March 31, 2024	65,292	(268)	145	(36)	(1.48) yen

2. Explanation for the difference

Net sales for the fiscal year ended March 31, 2025 were generally in line with expectations, due to steady growth in sales of Closed Drug Mixing/Infusion Systems, which we are promoting as a core business, as well as steady growth in sales of Blood Bags and AV Fistula Needles, which are our mainstay products overseas.

Operating profit was lower than the previous forecast due to a decline in the operating rate at the production base in the Philippines as a result of production adjustments by overseas customers to adjust their inventories, a review of assets including the disposal of long-term inventory, and the recording of foreign exchange losses due to unfavorable exchange rates and higher-than-expected income taxes.

For the fiscal year ended March 31, 2025, the Company plans to pay a year-end dividend of 8.50 yen per share.

END